Key facts
- This page summarizes Henry Ji's Form 4 filing for Sorrento Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Mar 2023, 19:52.
Henry Ji - 17 Mar 2023 Form 4 Insider Report for Sorrento Therapeutics, Inc.
- Reporting relationship
- President, CEO and Chairman of the Board of Directors, Director
- Issuer ticker
- N/A
- Reported as of
- 17 Mar 2023
- Net transaction value
- +$15,653
- SEC form
- 4
- Accepted by SEC
- 20 Mar 2023, 19:52:53 UTC
- Prior SEC filing
- 17 Jan 2023
- Next SEC filing
- 02 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Henry Ji, Ph.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Henry Ji filed Form 4 for Sorrento Therapeutics, Inc. on 20 Mar 2023.
Change
- Previous filing in this sequence was filed on 17 Jan 2023.
- Current net transaction value: +$15,653.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRNEQ
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $15,653
- Shares
- +19,500
- Change %
- +3900%
- Price
- $0.8027
- Shares after
- 20,000
- Date
- 17 Mar 2023
- Ownership
- By BioVintage, Inc.
- Footnotes
- F1, F2
SRNEQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,265,805
- Date
- 17 Mar 2023
- Ownership
- Direct
SRNEQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,271,693
- Date
- 17 Mar 2023
- Ownership
- See Footnote
- Footnotes
- F3
SRNEQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 40,000
- Date
- 17 Mar 2023
- Ownership
- By spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SRNEQ
transaction
Derivative
Put Option (obligation to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -195
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Mar 2023
- Ownership
- By BioVintage, Inc.
- Underlying class
- Common Stock
- Underlying amount
- 19,500
- Exercise price
- $0.8027
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On December 30, 2022, the Issuer's Board of Directors declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of common stock, par value $0.0001 per share, of Scilex Holding Company ("Scilex Common Stock") for each one share of common stock, par value $0.0001 per share, of the Issuer ("Sorrento Common Stock"). The Put Option written by the Reporting Person on August 26, 2022 (the "Put Option") was previously reported at an exercise price of $5.50 per share of Sorrento Common Stock, which was adjusted as a result of the Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,730 shares of Scilex Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Scilex Common Stock. The Put Option settled on March 17, 2023 and resulted in the Reporting Person
Footnote F2
(Continued Footnote 1) acquiring 19,500 shares of Sorrento Common Stock at a price of $0.80268 per share of Sorrento Common Stock, in addition to 2,730 shares of Scilex Common Stock at a price of $8.6002 per share of Scilex Common Stock.
Footnote F3
Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.
SEC remarks
President, CEO and Chairman of the Board of Directors